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SUMMARY – Th is prospective study in prevalent dialysis patients investigated prognostic prop-
erties of low triiodothyronine syndrome, protein-energy wasting and chronic infl ammation. Ninety-
four prevalent dialysis patients were followed-up for a median of 39 months. Demographic, anthro-
pometric and biochemical parameters were collected at baseline. Univariate and multivariate analysis 
was done using Cox regression analysis. ROC curve analysis using survival status as a classifi cation 
variable was performed with the goal of determining optimal cut-off  values for numerical variables. In 
our population, low total triiodothyronine (hazard ratio (HR) 2.19, p=0.038), catheter as vascular ac-
cess (HR 2.76, p=0.023), higher vintage (HR 1.01, p=0.014) and higher Charlson comorbidity index 
(HR 1.28, p=0.017) were statistically signifi cantly associated with inferior survival. In our group of 
steady-state dialysis patients, total triiodothyronine seemed to be the strongest predictor of inferior 
survival among thyroid hormones. Taking this parameter into account, it was possible to identify pa-
tients at an increased risk of death even after adjustment for other prognostically relevant variables. 
However, after further adjustment for signifi cant risk factors, the impact of C-reactive protein and 
albumin on survival disappeared due to the overlapping prognostic properties. We concluded that 
triiodothyronine was an independent prognostic factor in our study group.
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Introduction
Patients with end-stage renal disease (ESRD) are 
known to have a higher risk of mortality and morbid-
ity than the general population. Risk factors for mor-
tality in this group of patients are unique since there is 
a high prevalence of elderly patients with multiple co-
morbidities. Also, they have survived long enough to 
develop kidney failure. Th ere is the need to develop a 
special predictive model that could be applied to 
ESRD patients. Research has been focused on bio-
markers that could be novel risk factors that increase 
the accuracy of prognosis in patients with ESRD1.
One of the studied mortality risk markers in pa-
tients with ESRD is triiodothyronine (T3), whether in 
its free (fT3) or bound form (T3). Reduction of T3 
levels, while the levels of thyroid-stimulating hormone 
(TSH) remain in the reference range, is known as the 
low T3 syndrome. It is the most frequently observed 
thyroid hormone alteration in ESRD patients2-4. 
Chronic kidney disease aff ects both the hypothala-
mus-pituitary-thyroid axis and thyroid hormone pe-
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ripheral metabolism. Reduction in T3 concentrations 
has been linked to a decrease in peripheral synthesis of 
T3 from thyroxine (T4)2. It has been shown in many 
survival studies so far that low T3 syndrome is a risk 
factor for mortality both in hemodialysis (HD)5-9 and 
peritoneal dialysis (PD) patients10,11.
Another novel mortality biomarkers in ESRD pa-
tients are protein-energy wasting (PEW) and chronic 
infl ammation1. PEW is a state of decreased body stores 
of protein and fat masses. It can result from inadequate 
diet. However, in kidney disease there are some spe-
cifi c causes such as infl ammatory processes, intercur-
rent catabolic illnesses, nutrient losses into dialysate, 
metabolic acidosis, resistance to insulin, growth hor-
mone, and insulin-like growth factor-1, hyperglucago-
nemia, hyperparathyroidism, and loss of blood into the 
hemodialyzer, into stool or by blood drawing12. Studies 
in well-characterized hemodialysis populations indi-
cate that C-reactive protein (CRP) levels (as a marker 
of chronic infl ammation) are a consistent predictor of 
survival1, whereas serum albumin is known as a nega-
tive acute phase reactant, but also as one of the markers 
of PEW13.
In complex processes of acute and chronic infl am-
mation in patients with ESRD, studies have shown 
strong association between infl ammation markers and 
low T3 syndrome, where fT3/T3 was proven to be a 
signifi cant and independent predictor of survival14-16. 
On the other hand, Ozen et al. showed in a large co-
hort of prevalent hemodialysis patients that fT3 was a 
strong predictor of mortality in crude and adjusted 
Cox models including albumin or high-sensitivity 
CRP (hsCRP); however, after further adjustment for 
both albumin and hsCRP, the impact of fT3 on mor-
tality disappeared17. Another study performed by 
Fernández-Reyes et al. showed that low fT3 levels 
were not predictive of long-term mortality in a sub-
group of stable HD patients, who could survive for 
more than 12 months18.
Our study aimed to investigate the steady-state 
correlation of thyroid hormones, CRP and serum al-
bumin (and other surrogates of PEW) with mortality 
in our group of dialysis patients. Furthermore, taking 
into account a complex mortality risk factor profi le of 
dialysis patients19, we studied correlations of available 
known risk factors with mortality in our patients, 




In this observational prospective cohort study, 
prevalent HD and PD patients treated at Sestre mi-
losrdnice University Hospital Centre in Zagreb and 
Dr Tomislav Bardek General Hospital in Koprivnica, 
were enrolled. Baseline demographic, anthropometric 
and biochemical parameters were collected from April 
to December 2014. September 20, 2017 was consid-
ered as the end of the study. Survival was determined 
from the day of enrolment, with a median follow-up of 
39 months. Patients were censored at transplantation 
or when completing the follow-up period, with no loss 
of follow-up in any patient. Th e study exclusion crite-
ria were formerly diagnosed or present signs of hyper- 
or hypothyroidism, as well as infl ammatory illness, 
malignancy, use of drugs that alter thyroid function 
(amiodarone, propranolol, lithium) and unwillingness 
to participate. When we began our study, there were 
105 patients, but after the baseline measurements were 
performed, 11 patients had to be excluded due to sub-
clinical hypothyroidism (TSH ≥5 mIU/L) and clini-
cally unrecognized infl ammatory illness (CRP >30 
mg/L). Th ere remained 94 patients, 50 (53.2%) males 
and 44 (46.8%) females, median age 64 years, inter-
quartile range (IQR) 57.3-76. Patient characteristics 
are shown in Table 1. Th e study protocol was approved 
by Ethics Committees of the Sestre milosrdnice Uni-
versity Hospital Centre from Zagreb and Dr Tomislav 
Bardek General Hospital from Koprivnica. A signed 
informed consent was obtained from each patient.
Methods
Hemodialysis patients were dialyzed three times 
weekly for four hours, through either an arteriovenous 
fi stula or central venous catheter, using a polysulfone 
dialyzer 1.6-1.8 m², bicarbonate dialysis solution with 
dialysate fl ow 500 mL/min and blood fl ow rate 300 
mL/min. Th e Kt/V as a measure of dialysis adequacy 
was checked weekly and targeted above 1.2. Blood was 
drawn before the start of hemodialysis treatment from 
the inserted dialysis needle or the arterial port of di-
alysis circuit, before contact of blood with dialyzer and 
before heparin administration. Peritoneal dialysis pa-
tients were treated with four 1.5- to 2-liter exchanges 
four times per day using standard dialysates containing 
glucose and icodextrin. Using the mentioned dialysis 
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prescription, the total Kt/V urea was aimed at mini-
mum 1.7 per week.
At the beginning of the study, data on age, gender, 
type of dialysis, type of dialysis access, disease that 
caused ESRD, smoking habits and vintage (the length 
of time being treated with dialysis measured in 
months) were collected. Patients were measured for 
their body height (cm), weight (kg), body mass index 
(BMI, kg/m2) and percentage of fat tissue (using a 
standard caliper, in millimeters; skinfold thickness was 
measured at the rear part of the upper arm, two centi-
meters laterally of the umbilicus and at the front part 
of the thigh; it was measured at the beginning of di-
alysis treatment, on the second dialysis in the week). 
Comorbidity was evaluated using modifi ed Charlson 
comorbidity index (a method of predicting mortality 
by classifying or weighting comorbidities), without 
patient age included, as it was considered separately.
Laboratory data obtained at the beginning of the 
second weekly hemodialysis session and the regular 
monthly check-up were considered baseline values in 
Table 1. Patient demographic and anthropometric 
characteristics

















Vintage (length of time 
on dialysis in months)
27 IQR (14.3-60.8)























Body height (cm) 165 IQR (158-173.8)
Body weight (kg) 74 IQR (62-85.1)
Body mass index (kg/m²) 26.1 IQR (23-31.8)
Percentage of body fat (%) 19 IQR (15-24.8)
Charlson comorbidity index 6 IQR (4-7)
IQR = interquartile range; HD = hemodialysis; AV = arteriovenous; 
Kt/V = measure of dialysis adequacy; ESRD = end-stage renal dis-
ease; cm = centimeter; kg = kilogram; kg/m² = kilogram per cubic 
meter
Table 2. Baseline laboratory parameters





Platelets (x10e9/L) 176 IQR (138.3-208.5)
Uric acid (μmol/L) 327.2 IQR (296-370)
Creatinine (μmol/L) 662.1±196.7
Total cholesterol (mmol/L) 4.1±0.8
HDL cholesterol (mmol/L) 1.12 IQR (0.9-1.4)
LDL cholesterol (mmol/L) 2.5 IQR (2.1-2.9)
Triglycerides (mmol/L) 1.4 IQR (0.9-2)
Calcium (mmol/L) 2.2±0.2
Phosphates (mmol/L) 1.5 IQR (1.1-1.8)
Serum iron (μmol/L) 12 IQR (9.7-15.2)
UIBC (μmol/L) 24.8±9
TIBC (μmol/L) 36.4 IQR (32.8-41.3)
Transferrin saturation (%) 32 IQR (25.5-43.6)
Total protein (g/L) 65.3±5.5
Albumin (g/L) 38.3±3.5
CRP (mg/L) 5.7 IQR (2-10.6)
Ferritin (ng/mL) 631.4 IQR (291-746.8)
PTH (pg/mL) 249 IQR (131.3-425)
Total T3 (nmol/L) 1.1 IQR (1-1.3)
fT3 (pmol/L) 2.3 IQR (2.1-2.5)
Total T4 (nmol/L) 64.1 IQR (55.5-74.1)
fT4 (pmol/L) 12±1.7
TSH (mIU/L) 1.5±0.7
IQR = interquartile range; RBC = red blood count; MCV = mean 
corpuscular volume; WBC = white blood cell count; HDL = high-
density lipoprotein; LDL = low-density lipoprotein; UIBC = un-
saturated iron binding capacity; TIBC = total iron binding capacity; 
CRP = C-reactive protein; PTH = parathyroid hormone; T3 = tri-
iodothyronine; fT3 = free triiodothyronine; T4 = thyroxine; fT4 = 
free thyroxine; TSH = thyroid-stimulating hormone
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PD patients (Table 2). Plasma analyses of thyroid hor-
mones and TSH were performed using Abbott com-
mercially available Abbott assays (Abbott Laborato-
ries, Zagreb, Croatia). All other biochemical analyses 
were performed on an Olympus AU2700 analyzer us-
ing original Beckman Coulter assays (Beckman Coul-
ter, Zagreb, Croatia).
Statistical analysis
Th e normality of distribution of numerical vari-
ables was tested using the Kolmogorov-Smirnov test. 
Normally distributed numerical variables were ex-
pressed as arithmetic mean ± standard deviation (SD), 
and were compared between the groups using the T-
test. Non-normally distributed numerical variables 
were expressed as median and IQR, and were com-
pared between the groups using the Mann Whitney U 
test. Correlation between numerical variables was as-
sessed using Pearson or Spearman correlation depend-
ing on their normality of distribution. Categorical 
variables were expressed as number and proportion, 
and were compared between the groups using the χ2-
test or Fisher exact test when appropriate. Survival 
analyses were based on the Kaplan-Meier method. 
Univariate and multivariate analysis of factors associ-
ated with survival of patients was performed using the 
Cox regression analysis. ROC curve analysis using 
survival status as a classifi cation variable was per-
formed to determine optimal cut-off  values for nu-
merical variables. Th e level of statistical signifi cance 
was set at p<0.05. All analyses were performed using 
the MedCalc Statistical software, version 17.8.1 
(MedCalc Software bvba, Ostend, Belgium).
Results
Th yroid hormones and TSH and their clinical 
and laboratory correlations
Th e mean TSH value was 1.5±0.7 mIU/L. Higher 
TSH was statistically signifi cantly associated with 
lower uric acid (Rho -0.22, p=0.033), lower unsatu-
rated iron binding capacity (UIBC) (Rho -0.25, 
p=0.014) and higher transferrin saturation (Rho 0.22, 
p=0.033). In our cohort of patients with normal TSH 
values, there was no statistically signifi cant association 
of TSH with other thyroid hormones.
Th e median total T3 value was 1.1 nmol/L, IQR 
(1-1.3). Higher total T3 was statistically signifi cantly 
associated with younger age (Rho -0.25, p=0.017), 
higher body weight (Rho 0.2, p=0.049), higher red 
blood cell count (RBC) (Rho 0.24, p=0.021), lower 
mean corpuscular volume (MCV) (Rho -0.26, 
p=0.010), higher albumin (Rho 0.27, p=0.008), lower 
ferritin (Rho -0.22, p=0.031), higher fT3 (Rho 0.35, 
p=0.001) and higher total T4 (Rho 0.34, p=0.001).
Th e median fT3 value was 2.3 pmol/L, IQR (2.1-
2.5). Higher fT3 was statistically signifi cantly associ-
ated with peritoneal dialysis (median 4.36 vs. 2.23, 
p<0.001), younger age (Rho -0.24, p=0.020), lower 
Charlson comorbidity index (Rho -0.35, p=0.001), 
higher body height (Rho 0.34, p=0.001), higher body 
weight (Rho 0.33, p=0.001), higher uric acid (Rho 
0.27, p=0.010), higher UIBC (Rho 0.36, p<0.001), 
higher total iron binding capacity (TIBC) (Rho 0.41, 
p<0.001), lower transferrin saturation (Rho -0.21, 
p=0.044), higher albumin (Rho 0.25, p=0.014), higher 
total T3 (Rho 0.35, p=0.001), higher total T4 (Rho 
0.36, p<0.001) and higher fT4 (Rho 0.41, p<0.001).
Th e median total T4 value was 64.1 nmol/L, IQR 
(55.5-74.1). Higher total T4 was statistically signifi -
cantly associated with peritoneal dialysis (median 88.8 
vs. 62.6, p=0.001), higher Kt/V (Rho 0.29, p=0.005), 
lower serum iron (Rho -0.25, p=0.017), higher UIBC 
(Rho 0.31, p=0.003), higher TIBC (Rho 0.21, p=0.039), 
lower transferrin saturation (Rho -0.31, p=0.003), 
lower parathyroid hormone (PTH) (Rho -0.22, 
p=0.038), higher total T3 (Rho 0.34, p=0.001), higher 
fT3 (Rho 0.36, p<0.001) and higher fT4 (Rho 0.86, 
p<0.001).
Th e mean fT4 value was 12±1.7 pmol/L. Higher 
fT4 was statistically signifi cantly associated with peri-
toneal dialysis (median 14.4 vs. 11.72, p=0.003), high-
er Kt/V (Rho 0.25, p=0.015), lower serum iron (Rho 
-0.21, p=0.042), higher UIBC (Rho 0.26, p=0.011), 
lower transferrin saturation (Rho -0.28, p=0.006), 
lower PTH (Rho -0.25, p=0.014), higher fT3 (Rho 
0.41, p<0.001) and higher total T4 (Rho 0.86, 
p<0.001).
Survival of patients
Th e median follow up of our patients was 39 
months. Forty-two patients died during the follow up 
period. Th e most common causes of death were sud-
den cardiac death in 17/94 (40.5%), sepsis in 17/94 
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(40.5%), disseminated malignant disease in 2/42 
(4.8%), cerebrovascular insult in 2/42 (4.8%) patients, 
and hepatocellular carcinoma, myocardial infarction, 
suspected pulmonary embolism and unknown cause of 
death in one patient each. Survival curve for all pa-
tients is shown in Figure 1A. Median survival was not 
reached; the 3-year survival rate was 51.4%.
Optimal cut-off  values with best survival discrimi-
natory properties for thyroid hormones were deter-
mined using ROC curve analysis. Th e cut-off  for TSH 
Fig. 1. (A) Survival curve for all patients; (B) higher TSH; (C) lower total T3; and (D) lower fT3 were 
associated with inferior survival; (E) total T4; and (F) fT4 were not signifi cantly associated with survival.
*statistically signifi cant at p<0.05; TSH = thyroid-stimulating hormone; T3 = triiodothyronine; fT3 = free triiodothyronine; 
T4 = thyroxine; fT4 = free thyroxine; HR = hazard ratio
Nataša Črne Fureš et al. Mortality risk factors in dialysis patients
454 Acta Clin Croat, Vol. 57, No. 3, 2018
was set at >1.8 mIU/L. Although all patients had TSH 
values within the reference range, patients with higher 
TSH values experienced shorter survival in compari-
son to those with lower TSH values at baseline, as 
shown in Figure 1B (hazard ratio (HR) 1.58, p=0.037). 
Both groups experienced similar survival for the peri-
od of 2 years, then survival curves started to diverge. 
Th e cut-off  for total T3 was set at <1 nmol/L; patients 
with lower total T3 levels had inferior survival in com-
parison to patients with higher (normal) total T3 lev-
els, as shown in Figure 1C (HR 1.97, p=0.038). Th e 
cut-off  for fT3 was set at >2.29 pmol/L; patients with 
lower fT3 similarly had inferior survival in comparison 
to patients with higher (normal) fT3 values, as shown 
in Figure 1D (HR 2.94, p=0.003). Th e cut-off  values 
obtained for total T4 and fT4 were <86 nmol/L and 
>10.84 pmol/L, respectively. Total T4 (p=0.158) and 
fT4 (p=0.341) were not statistically signifi cantly asso-
ciated with survival in our cohort of patients.
We compared prognostic properties of diff erent 
thyroid hormones in a Cox regression model contain-
ing TSH, total T3, fT3, total T4 and fT4, as shown in 
Table 3. Low total T3 (HR 2.26, p=0.019), low fT3 
(HR 2.83, p=0.005) and high-normal TSH (HR 2.03, 
p=0.033) each bore an independent prognostic poten-
tial as they were able to retain statistical signifi cance 
and predict survival independently of each other.
Other parameters that were univariately associated 
with survival were catheter as venous access (HR 2.44, 
p=0.008), age (HR 1.05, p=0.001), vintage (HR 1.01, 
p=0.034), Charlson comorbidity index (HR 1.39, 
p<0.001), body height (HR 0.07, p=0.021), albumin 
(HR 0.88, p=0.008) and CRP (HR 1.04, p=0.006). We 
further investigated prognostic properties of thyroid 
hormones in a Cox regression analysis model includ-
ing total T3, fT3, TSH and other factors mentioned 
above that were univariately associated with survival 
and gender, as shown in Table 4. Low total T3 (HR 
2.19, p=0.038), catheter as venous access (HR 2.76, 
p=0.023), higher vintage (HR 1.01, p=0.014) and 
higher Charlson comorbidity index (HR 1.28, 
p=0.017) remained statistically signifi cantly associated 
with inferior survival.
Discussion
Study results showed that in our group of steady-
state dialysis patients, total T3 seemed to be an inde-
Table 3. Cox regression analysis investigating associations 
of thyroid hormones with survival
Variable HR; 95% CI p




















*statistically signifi cant at p<0.05; 95% CI = 95% confi dence inter-
val; HR = hazard ratio; T3 = triiodothyronine; fT3 = free triiodo-
thyronine; TSH = thyroid-stimulating hormone; T4 = thyroxine; 
fT4= free thyroxine
Table 4. Cox regression model investigating associations 
of total T3, fT3, TSH and other univariately signifi cant 
variables with survival
Variable HR; 95% CI p














































*statistically signifi cant at p<0.05; 95% CI = 95% confi dence inter-
val; HR = hazard ratio; T3 = triiodothyronine; fT3 = free triiodo-
thyronine; TSH = thyroid-stimulating hormone; CRP = C-reactive 
protein
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pendent predictor of inferior survival among thyroid 
hormones. It could identify patients at an increased 
risk of death even after adjustment for other prognos-
tically relevant variables. It was interesting to see that 
the higher values of TSH, when using only thyroid 
hormones in the analysis, were a signifi cant mortality 
risk, even though all the TSH values were in the refer-
ence range since we were focusing exclusively on the 
low T3 syndrome. However, when we included other 
statistically relevant confounding factors, TSH values 
lost their signifi cance.
Th e results from earlier studies showed that serum 
albumin and CRP were signifi cantly related with all-
cause mortality13 and that the CRP levels were a con-
sistent predictor of survival in hemodialysis popula-
tions1. However, in our study, after further adjustment 
for fT3, T3, TSH and other signifi cant confounding 
factors, the impact of CRP and albumin on survival 
disappeared due to overlapping prognostic properties. 
We concluded that, although it is known that low T3 
syndrome and PEW are interrelated15,16, in our group 
of patients T3 had greater infl uence on survival.
It has been recognized that all-cause and cardio-
vascular mortality is consistently higher in long-term 
dialysis patients with derangements in thyroid func-
tion test results. It is a question whether it would be 
cost-eff ective to screen for thyroid function among 
patients with ESRD20. When validating a potential 
new prognostic biomarker, there are four criteria to 
consider. Th e fi rst one is accuracy, which is the ability 
to reliably identify individuals at a greater risk of the 
adverse clinical outcome of interest. Th e second one is 
simplicity (for example, ease of measurement). Th e 
third one is the cost (biomarkers should be inexpensive 
and cost-eff ective), and the last one is the relevance of 
the information provided by the biomarker21. Accord-
ing to the results of our study, and to the available sci-
entifi c information gathered so far, it is our opinion 
that T3 should be considered as an important novel 
prognostic factor that should be taken into consider-
ation when analyzing survival chances of patients on 
dialysis.
Furthermore, in our study, using a central venous 
catheter (CVC) as vascular access in hemodialysis pa-
tients proved to be a signifi cant mortality risk factor. 
Th is fi nding is in accordance with the results of an-
other study comparing diff erent types of vascular ac-
cess (CVC, arteriovenous fi stulas (AVF) and arterio-
venous grafts (AVG))22. In this study, the survival rate 
among patients in whom hemodialysis was initiated 
with AVF was signifi cantly higher than that in pa-
tients in whom hemodialysis was initiated with AVG 
or CVC22. Patients who started hemodialysis and were 
using a venous catheter were at a 47% higher death 
risk compared with patients who were using an AVF. 
Th is association remained unaltered after adjustment 
for the potential confounding factors and after ac-
counting for frequent changes in access type over 
time23. What is interesting about our fi nding is that, to 
the best of our knowledge, there has not been a study 
that investigated the correlation of thyroid hormones 
with mortality in dialysis patients, alongside other 
mortality risk factors, which also included the hemo-
dialysis access. For this reason, we would suggest that 
hemodialysis vascular access be taken into account as 
an essential risk factor in the future survival studies.
Th e results of our study confi rmed once more that 
Charlson comorbidity index is a valid tool for assess-
ing comorbidity burden in dialysis patients24-26. Also, 
following previous studies27, the dialysis vintage is a 
signifi cant mortality risk.
Risk prediction models can be used to inform the 
patients undergoing renal replacement therapy about 
their survival chances. Hemke et al. showed that a sim-
ple model based only on registry data could be en-
hanced by adding readily available clinical parameters, 
such as cholesterol, phosphate, and albumin28. Th e as-
sociations among the main risk factors for death in 
hemodialysis patients are complex. A study by Kanda 
et al. showed that simultaneous evaluation of multiple 
risk factors could accurately assess patient prognosis 
and identify patients at an increased risk of death19. 
Based on the results of our study, we agree with the 
conclusions of the studies above regarding the neces-
sity of multiple mortality risk factor approach in as-
sessing prognosis of ESRD patients.
Our study had some limitations. Th e cohort had 
less than 100 patients, and the median follow up of our 
patients was 39 months. Th e question remains whether 
the parameters that were statistically signifi cant would 
remain signifi cant if the study group was larger and 
the follow up longer. Furthermore, we did not consider 
blood pressure as a confounder. It was proven that 
lower blood pressure in patients on hemodialysis (pre-
dialysis systolic <110 mm Hg), as well as higher blood 
pressure (predialysis systolic 150-159 mm Hg) was as-
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sociated with higher mortality29. Finally, it is a ques-
tion whether measures that we included in the study, 
such as serum albumin, BMI and percentage of fat tis-
sue, were adequate to assess completely the presence of 
PEW. We were unable to assess dietary protein intake 
or dietary energy intake, which are considered as com-
ponents of this syndrome12.
In conclusion, T3 seems to be the most reliable 
predictor of inferior survival among thyroid hormones. 
It could identify patients at an increased risk of death 
even after adjustment for other prognostically relevant 
variables, and it should be considered as an important 
mortality risk factor in evaluating the prognosis of 
ESRD patients.
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Sažetak
POVEZANOST SINDROMA NISKOG TRIJODTIRONINA, PROTEINSKO ENERGETSKE 
POTHRANJENOSTI I KRONIČNE UPALE SA SMRTNOŠĆU PREVALENTNIH DIJALIZNIH BOLESNIKA
N. Črne Fureš, M. Lucijanić, I. Žabić, K. Altabas i D. Pavlović
Cilj je bio istražiti prognostička svojstva sindroma niskog trijodtironina, proteinsko energetske pothranjenosti i kronične 
upale te drugih poznatih rizičnih čimbenika sa smrtnošću prevalentnih dijaliznih bolesnika. Ukupno 94 prevalentnih dija-
liznih bolesnika prospektivno je praćeno kroz medijan od 39 mjeseci. Na početku istraživanja sakupljeni su demografski, 
antropometrijski i biokemijski parametri. Učinjena je univarijatna te multivarijatna analiza primjenom Coxove regresijske 
analize. Kako bismo odredili optimalne granične vrijednosti numeričkih varijabla primijenjena je ROC analiza krivulje 
 koristeći preživljenje kao klasifi kacijsku varijablu. U našoj populaciji bolesnika su nizak ukupni trijodtironin (hazard ratio 
(HR) 2,19; p=0,038), kateter kao vaskularni pristup (HR 2,76; p=0,023), duži vintage (HR 1,01; p=0,014) i viši Charlson 
indeks komorbiditeta (HR 1,28; p=0,017) bili statistički značajno povezani s lošijim preživljenjem. U našoj skupini stabilnih 
dijaliznih bolesnika ukupni trijodtironin je među hormonima štitnjače bio najjači predskazatelj lošijeg preživljenja. Također, 
i nakon prilagodbe za druge prognostički značajne varijable vrijednost trijodtironina se i dalje može koristiti u prognozi 
bolesnika na dijalizi. Nakon daljnje analize prilagođene za druge značajne čimbenike rizika utjecaj C-reaktivnog proteina i 
albumina na smrtnost je nestao zbog prognostičkih svojstava koja se podudaraju. Zaključno, smatramo da je ukupni trijodti-
ronin bio neovisan prognostički čimbenik u našoj skupini bolesnika.
Ključne riječi: Dijaliza; Netireoidna bolest štitnjače; Upala; Rizični čimbenici; Hrvatska
